Short answer
Axogen, Inc. (AXGN) filed an 8-K current report with the SEC on September 10, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2), Item EX-99.3 (Exhibit EX-99.3). $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products.
Axogen, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $200.0M cash acquisition of BioCircuit, adding NerveTape and ConformaWrap peripheral-nerve repair products
- Funding planned through public offering of 4,910,000 shares at $42.50, with 736,500-share overallotment option
- Gross offering proceeds of approximately $208.7M before expenses, intended to fund the acquisition
- Fourth-quarter 2026 closing depends on IP-license consent, note conversion and electronics-business spin-out
- Integration execution and uncertain commercial benefits create material acquisition risk; no termination fee disclosed
Item 7.01 · Regulation FD Disclosure
- Merger Agreement announcement signals a proposed strategic transaction for Axogen shareholders
- Investor presentation provides management’s rationale and transaction details in Exhibit 99.2
- Offering pricing announcement indicates concurrent capital raising, with terms in Exhibit 99.3
Item EX-99.1 · Exhibit EX-99.1
- $200M cash acquisition of BioCircuit, subject to customary adjustments and $1.0M post-closing holdback
- NerveTape™ adds the first FDA-approved sutureless peripheral nerve repair device, broadening Axogen’s addressable market
- Funding planned through net proceeds from a public common-stock offering, creating potential shareholder dilution
- Expected fourth-quarter 2026 closing, conditional on customary approvals and BioCircuit electronics-business spin-out
- Management expects 2027 revenue contribution and first-year accretion to gross margin, adjusted EBITDA margin and adjusted EPS
Item EX-99.2 · Exhibit EX-99.2
- $200M cash BioCircuit acquisition, subject to customary adjustments, expected to close in Q4 2026
- Equity offering: $200M base size plus $30M option, substantially funding acquisition consideration and fees
- BioCircuit adds NerveTape, the first FDA-cleared sutureless nerve-repair device, with ~$24M annualized Q2 2026 revenue
- BioCircuit reported $11M 2025 revenue, ~80% gross margins, and $11M standalone EBITDA
- Management expects Year 1 revenue-growth and adjusted-EBITDA-margin accretion, while remaining free-cash-flow positive post-acquisition
Item EX-99.3 · Exhibit EX-99.3
- Public offering priced at $42.50 per share for 4,910,000 shares, generating expected gross proceeds of $208.7 million
- Underwriters hold a 30-day option for 736,500 additional shares, creating potential further dilution
- Substantially all net proceeds earmarked for cash consideration and expenses related to the BioCircuit Technologies acquisition
- Offering is not conditional on the BioCircuit acquisition, preserving funding but increasing general-purpose capital if the deal fails
- Expected closing September 11, 2026, subject to customary conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Axogen, Inc. 8-K filings
Get the next AXGN 8-K as it lands
Follow AXGN for push alerts, or ask the research agent what this filing means.